XML 67 R60.htm IDEA: XBRL DOCUMENT v3.24.3
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 26,930,284 26,020,265 26,968,640 25,210,492
Common Stock Options Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 12,520,579 13,806,283 12,885,829 14,054,478
Nonvested Restricted Stock Units Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 10,578,591 10,301,308 10,697,694 9,575,868
Nonvested Market-based Restricted Stock Units Outstanding Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 3,831,114 1,912,674 3,385,117 1,580,146